Back

Net clinical benefit of continued oral anticoagulants after successful AF ablation: a nationwide cohort study

30 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Anticoagulation in atrial fibrillation: safety and outcomes Oral Anticoagulation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Boyoung Joung

Yonsei University, Seoul (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Atrial fibrillation and frailty related variance in anticoagulation administration among patients with suspected ischaemic heart disease: the AFRAAID, SWEDEHEART study
Doctor S. Ingves (Norrkoping, SE)
Abstract Slides Video
Presentation thumbnail
Timing of anticoagulation therapy resumption among non-valvular atrial fibrillation (NVAF) patients with prior intracranial haemorrhage
Doctor W. Sun (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Anticoagulation strategies and clinical outcomes in atrial fibrillation patients developing renal deterioration during DOAC therapy
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
D-dimer: a less invasive way to rule out left atrial thrombus
Doctor S. Taerahkun (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Anemia and thrombocytopenia in patients with atrial fibrillation: a nationwide study.
Doctor M. Heikkinen (Helsinki, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Anticoagulation in atrial fibrillation: safety and outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Exploring the feasibility of discontinuing oral anticoagulant therapy in post-ablation atrial fibrillation patients with low stroke risk: a conceptual inquiry
1 April 2025
thumbnail
Congress Presentation
Net benefit of anticoagulation in subclinical device-detected atrial fibrillation: a Markov decision model analysis
1 April 2025
thumbnail
Congress Presentation
Catheter ablation is associated with reduced all-cause mortality in a real-world cohort of patients with atrial fibrillation and heart failure
31 August 2019
thumbnail
Congress Presentation
Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources